Your browser doesn't support javascript.
loading
Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1.
Liu, Xiao-Yu; Zhang, Ni; Zhang, Sheng-Xiao; Xu, Ping.
Afiliación
  • Liu XY; Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Zhang N; Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Zhang SX; Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
  • Xu P; Key laboratory of Cellular Physiology, Shanxi Medical University, Ministry of Education, Shanxi, China.
Eur J Neurosci ; 54(10): 7749-7769, 2021 11.
Article en En | MEDLINE | ID: mdl-34676939
ABSTRACT
Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon-like peptide-1 (GLP-1), a gut incretin hormone, has become a well-established treatment for T2DM and is likely to be involved in treating cognitive impairment. In this mini review, the similarities between AD and T2DM are summarised with the main focus on GLP-1-based therapeutics in AD.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Enfermedad de Alzheimer / Disfunción Cognitiva Límite: Humans Idioma: En Revista: Eur J Neurosci Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Enfermedad de Alzheimer / Disfunción Cognitiva Límite: Humans Idioma: En Revista: Eur J Neurosci Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: China